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Heterometallic titanium–gold complexes inhibit
renal cancer cells in vitro and in vivo†‡
Jacob Fernández-Gallardo,§a Benelita T. Elie,§ab Tanmoy Sadhukha,c
Swayam Prabha,cd Mercedes Sanaú,e Susan A. Rotenberg,bf Joe W. Ramos*g
and Maŕıa Contel*abg
Following recent work on heterometallic titanocene–gold complexes as potential chemotherapeutics for
renal cancer, we report here on the synthesis, characterization and stability studies of new titanocene
complexes containing a methyl group and a carboxylate ligand (mba ¼ S–C6H4–COO) bound to
gold(I)-phosphane fragments through a thiolate group [(h-C5H5)2TiMe(m-mba)Au(PR3)]. The compounds
are more stable in physiological media than those previously reported and are highly cytotoxic against
human cancer renal cell lines. We describe here preliminary mechanistic data involving studies on the
interaction of selected compounds with plasmid (pBR322) DNA used as a model nucleic acid, and with
selected protein kinases from a panel of 35 protein kinases having oncological interest. Preliminary
mechanistic studies in Caki-1 renal cells indicate that the cytotoxic and anti-migration effects of the
most active compound 5 [(h-C5H5)2TiMe(m-mba)Au(PPh3)] involve inhibition of thioredoxin reductase
and loss of expression of protein kinases that drive cell migration (AKT, p90-RSK, and MAPKAPK3). The
co-localization of both titanium and gold metals (1 : 1 ratio) in Caki-1 renal cells was demonstrated for 5
indicating the robustness of the heterometallic compound in vitro. Two compounds were selected for
further in vivo studies on mice based on their selectivity in vitro against renal cancer cell lines when
compared to non-tumorigenic human kidney cell lines (HEK-293T and RPTC) and the favourable
preliminary toxicity profile in C57BL/6 mice. Evaluation of Caki-1 xenografts in NOD.CB17-Prkdc SCID/J
mice showed an impressive tumor reduction (67%) after treatment for 28 days (3 mg per kg per every
other day) with heterometallic compound 5 as compared with the previously described [(h-C5H5)2Ti
{OC(O)-4-C6H4-P(Ph2)AuCl}2] 3 which was non-inhibitory. These findings indicate that structural
modifications on the ligand scaffold affect the in vivo efficacy of this class of compounds.
Introduction
For over three decades, complexes with metals other than
platinum have been explored as potential cancer chemothera-
peutics1 in order to overcome the drawbacks of cisplatin and
some of its derivatives. The challenges posed by these
compounds include both acquired or intrinsic resistance, and a
limited therapeutic window due to high toxicity leading to
undesired side effects.2,3
Titanocene dichloride (TDC, [(h-C5H5)2TiCl2]) was the rst
organometallic complex to enter clinical trials in 1993.4 This
compound exhibited considerable antitumor activity in both in
vitro and in vivo experimental models even against cisplatin-
resistant cells and tumors that are generally difficult to treat.5,6
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However, the efficacy of titanocene dichloride in phase II clin-
ical trials in patients with metastatic renal cell carcinoma7 or
metastatic breast cancer was too low to be pursued.8 To over-
come these problems, different follow-up TDC derivatives have
been developed, e.g. Titanocene Y, Titanocene Y* and Titano-
cene T22 (ref. 9–14) that were shown to be effective as potential
anti-cancer agents in vitro and in vivo. These derivatives display
a different mode of action than cisplatin since they produce
selected signicant renal tumor growth inhibition that warrants
further pharmacological and clinical investigation.
Gold complexes have emerged as another family of metal-
lodrugs with encouraging pharmacological proles. Gold
compounds have displayed signicant effects against tumors
resistant to cisplatin.15,16 In addition, it has been demonstrated
that for most gold compounds DNA is not the primary target. A
variety of alternative biochemical targets such as deacetylases,
specic proteases, protein kinases and polymerases have been
proposed for some of the gold(III) and gold(I) complexes.17–28
Seeking an enhancement of the anti-cancer properties of
these two families of metallodrugs, we and others have worked
on the design of titanium–gold heterometallic complexes. The
hypothesis is that the incorporation of two different cytotoxic
metals in the same molecule may improve their activity as anti-
tumor agents due to interaction of the different metals with
multiple biological targets (cooperative effect) or by the
improved chemicophysical properties of the resulting hetero-
metallic compound (synergism). It has been demonstrated that
a number of titanocene–gold complexes are more cytotoxic and
selective towards human cancer cell lines than the corre-
sponding monometallic moieties.29,30
Our rst synthetic approach was based on titanocene–gold
compounds with a cyclopentadienyl-phosphane linker moiety30
(compound 1, Chart 1). Species of this type showed enhanced
anti-cancer properties with respect to the monometallic coun-
terparts.29,30 However, due to the well-known hydrolysis of Cp–Ti
bonds at pH 7, we hypothesized that these heterometallic
compounds could potentially break into monometallic species
in physiological media or in vivo before reaching the tumors.
Indeed, we found that in some cases in solution the stability of
the compounds was low.30
In order to increase stability, we incorporated the second
metal to a ligand strongly bound to the titanium(IV) center to
ensure that heterometallic Ti–M species would remain aer
Ti–Cp hydrolysis occurs under physiological pH conditions.
Since Ti–O bonds are considerably stronger (DHf298 ¼ 662(16) kJ
mol1) than Ti–C (DHf298 ¼ 439 kJ mol1) or Ti–Cl (DHf298 ¼ 494
kJ mol1) bonds, we envisioned a carboxylate as the ideal group
to bind titanium(IV) centers (compounds 2 and 3, Chart 1).31
This strategy rendered compounds more stable than TDC and 1
in solution, and endowed them with relevant activity and
selectivity against human renal cancer cell lines as well as a
favourable preliminary toxicity prole in C57BL/6 mice.31
Thiolato-gold(I) phosphane complexes (such as Auranon)
have displayed relevant biological properties which are related
in most cases to their inhibitory properties on thioredoxin
reductase.32–34 We aimed to increase the cytotoxicity of hetero-
metallic Ti–Au compounds by the incorporation of thiolato
ligands coordinated to gold. Bifunctional ligand mba (derived
from 4-mercaptobenzoic acid (H2mba) Chart 2) was chosen as
an attractive candidate to covalently link both metal centres.
We report here on the synthesis and characterization of
new organometallic Ti–Au compounds with mba of the type
[(h-C5H5)2TiMe(m-mba)Au(PR3)] (R ¼ Ph, 5, R ¼ MPPF, 7). The
stability of these compounds in dimethyl sulfoxide (DMSO)
and phosphate buffer saline (PBS) was monitored by NMR and
UV-vis spectroscopy. We describe their in vitro activity against
human renal Caki-1 cancer cell lines, non-tumorigenic human
embryonic kidney cell lines HEK-293T, and human renal
proximal tubular cells (RPTC). We present studies of the effect
of compounds on cell death, interactions with DNA, and
inhibitory effects with thioredoxin reductase and certain
protein kinases implicated in our earlier study. In addition, we
report on the verication of activity in renal cancer cell lines
against these targets by 5 and the previously reported
[(h-C5H5)2Ti{OC(O)-C6H4-PPh2AuCl}2] (3, Chart 1) and
compare the pharmacokinetics and efficacy of compounds 3
and 5 in an in vivo evaluation of Caki-1 xenogras in
NOD.CB17-Prkdc SCID/J mice.
Chart 1 Previous heterometallic Ti–Au complexes synthesized in our
group.30,31
Chart 2 Previous and new bifunctional ligands employed by this
laboratory.
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The synthesis of the new heterometallic TiAu complexes is
depicted in Scheme 1. The reaction of one equivalent of the
corresponding mononuclear gold(I) complexes, 4 or 6, with one
equivalent of [(h-C5H5)2TiMe2] (with concomitant elimination
of one equivalent of methane) afforded [Cp2TiMe(m-mba)
Au(PR3)] (R ¼ Ph, 5, R ¼ MPPF, 7) in high yields as air- and
moisture-stable orange-coloured solids. Both heterometallic
compounds 5 and 7 turned out to be less acidic than titanocene
dichloride (see experimental section) and are soluble in DMSO/
H2O, DMSO/PBS or DMSO/media (1 : 99) mixtures at micro-
molar concentrations, which is relevant for subsequent bio-
logical testing.
The reaction in Scheme 1 did not yield the expected trinu-
clear TiAu2 species (like 2 and 3 in Chart 1 with the carboxylato-
phosphane linker) or as reported for ZrAu2 species with mba
ligands.35 The smaller size of titaniumwith respect to zirconium
may be the reason that the di-substitution reaction did not
proceed and bimetallic compounds TiAu were obtained instead.
Compounds 5 and 7 are examples of unusually stable methyl-
containing titanocene moieties that are stable as solids at air
and RT and in CDCl3 solution for at least 5 days. To the best of
our knowledge, this is the rst air- and moisture-stable Ti–Me
derivative.
Although the synthesis of gold compound 4 had been
previously reported,36,37 compound 4 as well as new compound 6
were synthesized in a more efficient manner31 following the
strategy established by Sordo and co-workers38 for the synthesis
of gold thiocarboxylate derivatives via selective deprotonation of
the thiol over the carboxylic acid (see Experimental section).
Compound 6was isolated as a pale orange solid in high yield. By
layering n-hexane over a solution of compound 6 in dichloro-
methane, we obtained crystals suitable for X-ray diffraction.
The crystals of compound 6 were determined to be triclinic
(space group P1) with Z ¼ 2 formula units in the unit cell. The
individual monomeric units (Fig. 1) form chains which show
hydrogen bonding at one end and Au–S groups at the other
(Fig. 2). The environment of the gold atoms is close to linear
[P–Au–S 177.31(5)] (Fig. 1). A selection of structural parameters
is given in Table 1. In the polymeric units (Fig. 2), the (MPPF)
Ph2P–Au–S moieties of neighbouring molecules are aligned
head to tail to form parallelograms with edges Au–S 2.3128(16),
Au–S* 3.374 Å and a diagonal Au–Au* of 4.351 Å.
This polymeric structure was previously described for similar
Hmba complexes.37 The main difference herein lies in the
intermolecular Au–Au* and AuS* distances: in this case, the
intermolecular Au–S* distances are considerably shorter than
the Au–Au* distances and very similar to the van der Waals radii
of the AuS pair [3.35 Å]. Therefore, since gold–gold distance is
larger than the sum of the van der Waals radii for two gold
atoms [3.60 Å], the AuS* contact is more likely to be the
Scheme 1 Preparation of heterometallic titanocene–gold complexes
[(h-C5H5)2Ti(CH3){OC(O)C6H4SAu(PR2R0)}] (R¼ R0 ¼ Ph, 5; R¼ Ph, R0 ¼
ferrocene, 7). (i) THF/toluene 1.5 : 1, RT, 1 h; (ii) acetonitrile/toluene
3 : 1, RT, 1 h.
Fig. 1 ORTEP view of the molecular structure of 6 showing the
labelling scheme. Labelling for hydrogen and some carbon atoms is
omitted for clarity. A drawing of the molecular structure containing
carbon atoms labelled is provided in the ESI.‡
Fig. 2 ORTEP view of the polymeric structure of 6 showing hydrogen
bonds (blue dotted line) and the Au–S weak interactions (red-brown
dotted line). Applied colour code as in Fig. 1.
Table 1 Selected structural parameters of complex 6 obtained from
X-ray single crystal diffraction studies. Bond lengths are given in Å and
angles in degrees
Au(1)–P(1) 2.2647(15) P(1)–Au(1)–S(1) 177.31(5)
Au(1)–S(1) 2.3128(16) P(1)–C(8)–Fe(1) 128.7(3)
P(1)–C(8) 1.789(6) Au(1)–S(1)–C(31) 105.1(2)
P(1)–C(11) 1.823(6) Z–Fe(1)–Z0 175.86
P(1)–C(21) 1.822(6)
S(1)–C(31) 1.770(6)
Distance Fe–Z (centroid of C5H4) 1.640
Distance Fe–Z0 (centroid of C5H5) 1.667
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5269–5283 | 5271































































































dominating contributor to the aggregation. No structural
anomaly was observed in the hydrogen bonds between the two
carboxylic groups.
The structures of complexes 5 and 7 depicted in Scheme 1
have been proposed on the basis of NMR and UV-vis spectros-
copy, mass spectrometry, and elemental analysis (see Experi-
mental section). Moreover, IR experiments and DFT
calculations were carried out in order to shed light on the
coordination mode of the carboxylate groups. The solid state IR
spectra of compounds 5 and 7 show that the carboxylate groups
are bonded to the titanium centre in a monodentate fashion
since the differences found between the symmetric and anti-
symmetric stretching bands39,40 are 346 cm1 and 348 cm1,
respectively, i.e. larger than 200 cm1.
These data are supported by the theoretical values obtained
by DFT calculations where the differences between the
symmetric and antisymmetric stretching bands39,40 were found
to be 328 cm1 and 330 cm1 for compounds 5 and 7, respec-
tively, thus indicating the monodentate coordination mode of
the carboxylic moieties (Fig. 3). In the ESI‡ section, data on
different optimizations are provided. All calculations performed
led to the species containing a monodentate carboxylate.
The stability of compounds 5 and 7 was evaluated by 31P{1H}
and 1H NMR spectroscopy in DMSO-d6, UV-vis spectroscopy in
DMSO/PBS solution and by mass spectrometry over time
(see ESI‡). NMR experiments were performed in neat DMSO-d6
due to the low solubility of the compounds in mixtures of
DMSO-d6/D2O in concentrations larger than 100 micromolar.
Titanocene dichloride is known to hydrolyze with a higher rate
in DMSO than in water.41 The half-life of 5 and 7 derivatives in
DMSO-d6 was found to be 8 and 32 hours respectively, i.e.
16-fold or 64-fold larger than that of 2 and 3 in the same
solvent.31 As reported for TDC, compounds 5 and 7 lose the
cyclopentadienyl groups in DMSO (most plausibly being
replaced by OH groups).31 Surprisingly, the methyl groups of
compounds 5 and 7 are hydrolysed at the same rate than the
cyclopentadienyl groups. Therefore, the longer half-life found
for compounds 5 and 7 in DMSO-d6 could indicate the positive
inuence of the di-covalent linker (m-mba) between the titanium
and the gold centres.
The UV-vis spectra of compounds 5 and 7 (micromolar
concentration) in 1 : 99 DMSO/PBS solution did not change over
time (24 h, see ESI‡) indicating that the hydrolysis is much
slower in solutions at physiological pH. Importantly, mass
spectrometry also indicated the presence of species containing
both titanium and gold in 1% DMSO/PBS solution aer 24 h
(see ESI‡).
Biological activity
Assays of cytotoxicity, cellular uptake, cell death and
migration
Cytotoxicity studies. The cytotoxicity of the heterometallic
complexes [(h-C5H5)2 TiMe(m-mba)Au(PR3)] (R ¼ Ph, 5, R ¼
MPPF, 7) and monometallic gold(I) complexes [Au(Hmba)PR3]
(PR3 ¼ PPh3 4;31 MPPF 6 in Scheme 1) was assayed by moni-
toring their ability to inhibit cell growth using the XTT assay
(see Experimental section). The cytotoxic activity of the
compounds was determined as described in the Experimental
section. In this assay, human renal Caki-1 cancer cell lines, non-
tumorigenic human embryonic kidney cell lines HEK-293T, and
human renal proximal tubular cells (RPTC) were incubated with
the indicated compound for 72 hours and compared for sensi-
tivity to cisplatin, titanocene dichloride and Titanocene Y.42 The
results are summarized in Table 2; data comparing both 24 and
72 hours can be found in the ESI.‡
The heterometallic compounds are considerably more toxic
to the renal cancer cell line (Caki-1 cells) than cisplatin, tita-
nocene dichloride and Titanocene Y. In addition, the hetero-
metallic compound 5 is far more toxic in the nanomolar range
than the monometallic gold compound 4 on these cells.
Importantly, compound 5 is considerably less toxic to the non-
tumorigenic human embryonic kidney cell line (HEK-293T) and
human renal proximal tubular cells than is 4. Heterometallic
compound 7 with phosphine MPPF exhibits cytotoxicity with
both Caki-1 and non-tumorigenic cell lines similar to that of
parent monometallic compound 6, but is much less selective
than 5 aer 72 h incubation.
Fig. 3 Optimized structures for heterometallic complexes 5 and 7.
Table 2 IC50 values (mM) in human cell lines were determined with
heterometallic TiAu compounds [(h-C5H5)2TiMe(m-mba)Au(PR3)] 5
and 7 monometallic [Au(Hmba)PR3] 4 and 6, cisplatin, titanocene
dichloride, and Titanocene Y. All compounds were dissolved in 1% of
DMSO and diluted with water before addition to cell culture medium
for a 72 h incubation period. Cisplatin and titanocene dichloride were
dissolved in H2O
Caki-1 HEK-293T RPTC
[Au(Hmba)(PPh3)] 4 2.76  0.35 1.11  0.65 3.87  0.15
Ti-Au 5 0.12  0.003 0.49  0.008 2.67  0.12
[Au(Hmba)MPPF] 6 3.6  0.342 3.0  0.07 3.78  0.13
Ti–Au 7 4.11  0.64 3.09  0.003 3.76  0.21
Cisplatin 29  4.11 3.27  0.13 —
[(h-C5H5)2TiCl2] >200 >200 —
Titanocene Y 29.42  4.18 >200 —
5272 | Chem. Sci., 2015, 6, 5269–5283 This journal is © The Royal Society of Chemistry 2015































































































We studied the effect of the combination of monometallic
gold compound 4 and titanocene dichloride in renal cancer cell
lines at 24 h which in all cases gave IC50 values > 100 mM (data
not shown). This fact supports the idea that there is indeed a
synergistic effect for the heterometallic complexes in their in
vitro activity on renal cancer cell lines.
Robustness of compound 5 and the co-localization of Au/Ti
metals in Caki-1 cells. In an attempt to determine the co-locali-
zation of Au and Ti metals in the Caki-1 cells, lysates of Caki-1
cells treated with 5 were analysed by Inductively Coupled
Plasma-Mass Spectromety (ICP-MS) to determine the amounts
of both metals (see Experimental section for details). Lysates of
Caki-1 cells receiving no drugs were employed as controls. It was
found that these cells have some basal levels of both the
elements present (3.5 mg Ti and 0.1 mg Au per mg cell protein).
When corrected for the background levels of the two elements
in the cell lysates, it was found that the levels of Ti and Au
demonstrated a stoichiometric ratio close to unity suggesting
that the compound is stable in intracellular environment. Fig. 4
shows that cellular levels of compound 5 increased with an
increase in the concentration of drug in the incubation media.
Increasing the drug concentration from 1 mM to 5 mM resulted
in a four-fold increase in the cellular levels of compound 5.
Elemental analysis (ICP-MS) conrmed that the stoichiometric
ratio of Au to Ti (0.96 in 1 mM and 0.95 in 5 mM) in the cell lysate
is close to unity, thus conrming that the compound is stable
when taken up in the cells.
Cell death assays. The induction of both apoptosis and
necrosis are known for gold compounds43 while titanocenes like
titanocene C, X and Y are known to induce apoptosis in
different cancer cell lines.13 In order to gain some insight into
the nature of the cytotoxicity that the most toxic and selective
heterometallic complex 5 induces in renal cancer cell lines, we
performed cell death assays for apoptosis with this compound
dissolved in 1% DMSO (see Experimental section for details)
and used either 1% DMSO alone in media (vehicle control) or
10 mM staurosporine (a known inducer of apoptosis) (positive
control).31
Aer incubation for 6 hours with 10 mM compound 5, the
appearance of peaks similar to that of staurosporine implicates
apoptosis as one basis for the cytotoxic effect of this compound
(Fig. 5).
Migration assays. In advanced tumors, increased cell migra-
tion is a hallmark of cancer cell invasion and metastasis.44,45 We
therefore set out to evaluate the anti-invasive properties of the
most active heterometallic titanocene–gold compounds
described in this and previous work (compounds 331 and 5,
respectively). Anti-invasive properties were evaluated by using a
wound-healing scratch assay (details and explanations on the
assay can be found on the ESI‡ section). Upon treatment with
compound 3 [(h-C5H5)2Ti{OC(O)CH2PPh2AuCl}2], cell migration
was slowed with 81% of the scratchle uninvaded (Fig. 6).
However, in highly metastatic Caki-1 cells treated with 0.1%
DMSO control, only 19% of the scratch remained uninvaded.
Treatment of these cells with 5 led to complete inhibition of
migration (Fig. 6). Also, striking morphological changes did
occur in cells treated with 5. We found that this compound
caused distinct rounding of the cells and that aer 12 hours of
Fig. 4 Cellular uptake of compound 5 in Caki-1 cells. The concen-
tration of compound 5 calculated based on Ti and Au content in the
cell lysates is similar suggesting that the compound is robust and both
the elements are co-localized in the cells.
Fig. 5 Cell death assays on Caki-1 cells induced by 5 (10 mM)
measured by using two-colour flow cytometric analysis, after 6 h of
incubation. 1% DMSO is vehicle control and staurosporine as positive
control.
Fig. 6 Scratch assay showing that compounds 3 and 5 interfere with
Caki-1migration. Panels show representative images of untreated cells
at time points up to 12 hours (top row), or cells treated with 3 (middle
row), and 5 (bottom row). The left column shows a representative
image of untreated Caki-1 cells immediately post-scratch (t ¼ 0 h). All
other panels show Caki-1 cells at 1 hour (t ¼ 1), 8 hours (t ¼ 8) or
12 hours (t ¼ 12) post-treatment. The graph represents results from
measurements of the area of the scratch from 4 separate and
randomly selected fields of view.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5269–5283 | 5273































































































incubation there was a complete loss of cell–cell contacts. Those
results clearly indicate anti-migratory properties for
compounds 3 and 5. The cytostatic and anti-migratory pheno-
types induced by new compound 5warrants further exploration.
Interactions with plasmid DNA
Since DNA replication is a key event for cell division, it is
among critically important targets in cancer chemotherapy.
Most cytotoxic platinum drugs form strong covalent bonds
with DNA bases.46 However, a variety of platinum compounds
act as DNA intercalators upon coordination to the appropriate
ancillary ligands.47 DNA was believed to be the target for tita-
nocene dichloride.38 Titanium accumulates in the cells in
nuclear heterochromatin and, to a minor extent, in the
nucleolus and ribosomes.48 Titanium–DNA adducts were
detected in A2780 cells treated with TDC and this compound
also inhibited DNA and RNA synthesis.49 However, most recent
reports on titanocene dichloride indicate that at physiological
pH it neither binds strongly to DNA nor suppresses DNA-
processing enzymes.50 Titanocene Y was recently shown to
interact weakly with DNA,51 consistent with the weak activity
observed with previously described TiAu2 compounds (2 and
3).31 DNA-interactions were tested with heterometallic
compounds 3 and 5, monometallic gold(I) derivatives 6 and 7,
titanocene dichloride, or cisplatin by using plasmid (pBR322)
DNA (Fig. 7). This plasmid has two main forms: OC (open
circular or relaxed form, Form II) and CCC (covalently closed
or supercoiled form, Form I). Agarose gel electrophoresis
assays were performed whereby decreased electrophoretic
mobility of both forms were taken as evidence of metal–DNA
binding. Generally, the slower the mobility of supercoiled DNA
(CCC, Form I), the greater the DNA unwinding produced by the
drug.52 For example, binding of cisplatin to plasmid DNA
results in decreased mobility of the CCC form and increased
mobility of the OC form (see lanes a–d for cisplatin in Fig. 7).
Treatment of plasmid DNA with increasing amounts of
monometallic Au(I) compounds 4 and 6 or heterometallic TiAu
derivatives 5 and 7 did not affect the mobility of the faster-
running supercoiled form (Form I) even at the highest molar
ratios (d). This result is in accordance with previously reported
results on a titanocene–gold(I) phosphine derivative
[(h5-C5H5)-(m-h
5:k1-C5H4PPh2)TiCl2]2Au]PF6 (Chart 2) and
other TiAu2 derivatives described by us [(h-C5H5)2Ti{OC(O)
RPPh2AuCl}2] (R ¼ –CH2– 2 and R ¼ –C6H4– 3).29,31
Inhibition of thioredoxin reductase
Changes in cell anti-oxidant capacity are a characteristic of
many chemo-resistant cancers, and overexpression of thio-
redoxin reductase (TrxR) in drug-resistant cells is part of a
critical defense and survival mechanism of cisplatin-resistant
cells, thus making this enzyme an important anti-cancer
target53,54 A number of gold(I) compounds with anticancer
properties are known to inhibit thioredoxin reductase isolated
from human placenta,53 rat liver32,55–60 or isolated from treated
cancer cells.34,61–63 One such example is the structurally related
gold-thiolato-phosphane compound (Auranon, AF) which
inhibits 50% of the enzymatic activity of isolated TrxR at
concentrations as low as 20 nM. AF also inhibits TrxR in human
breast MCF-7 cancer cells (4 mM inhibits 18% total TrxR
activity)62 and human ovarian A2780 cancer cells (10 mM inhibits
30% total activity).63 Therefore, we measured the activity of
thioredoxin reductase in Caki-1 cells, following incubation with
compounds 3, 5 and Auranon was used as a positive control.
We found thioredoxin reductase activity to be signicantly
lower in cells treated with 5 mM of either 3, 5 or Auranon with
an observed inhibition of 31.6%, 68.2%, and 74.1% respectively
aer a 5 hour incubation (Fig. 8).
The half maximal inhibitory concentration (IC50) values
were: 0.61 (0.002) mM for AF, 4.75 (0.048) mM for 3, and 0.88
(0.008) mM for 5 aer 12 hours. The similar values for AF and
compound 5 imply that the two compounds have similar
potencies in Caki-1 cells. However compound 5 is markedly
Fig. 7 Electrophoresis mobility shift assays for cisplatin, titanocene dichloride, heterometallic TiAu compounds 5 and 7 and monometallic
[Au(Hmba)(PR3)] 4 and 6 (see Experimental for details). DNA refers to untreated plasmid pBR322. (a, b, c and d) correspond tometal/DNAbp ratios
of 0.25, 0.5, 1.0 and 2.0 respectively.
Fig. 8 Thioredoxin reductase activity in 3, 5 or Auranofin treated Caki-
1 cells. Activity of Caki-1 thioredoxin reductase from soluble whole cell
lysates following incubation with 5 mM of 3, 5 or Auranofin for 5 hours.
5274 | Chem. Sci., 2015, 6, 5269–5283 This journal is © The Royal Society of Chemistry 2015































































































more toxic to Caki-1 cells than Auranon (IC50 ¼ 3.08 0.13 mM
for AF vs. 0.12  0.003 mM for 5) indicating that inhibition of
TrxR is not the only factor involved in the cytotoxic mechanisms
of these heterometallic compounds. The observed inhibitory
effect of 3 and especially 5 on thioredoxin reductase activity in
whole cell lysates indicates that this enzyme is a suitable
selective target for cancer therapy with this type of compounds.
Studies with protein kinases
Protein kinases have an important role in oncogenesis and
tumor progression, and therefore are frequently used as targets
for designing anticancer drugs that have included organome-
tallic complexes (Meggers and coworkers).64–66
In an effort to gain new insights into the mechanism of
action of heterometallic compounds, we performed immuno-
blotting assays on whole cell lysates of Caki-1 cells treated with
compounds 3 or 5 to evaluate their effects on the expression
levels of selected protein kinases, namely p90-RSK, AKT, and
MAPKAPK3. Compound 5 produced dramatic decreases in
expression of all three protein kinases by 12 hours post-treat-
ment (Fig. 9A). In contrast, no loss of expression was noted
following a similar treatment with compound 3 (Fig. 9B and
ESI‡). These ndings indicate that compound 5 acts through a
transcriptional or translational mechanism aer the rst hour
of treatment, thereby displacing direct drug–kinase interactions
that we have observed in vitro (described in the ESI‡). Since all
three enzymes have been implicated in promoting cell migra-
tion and therefore are strong targets for anti-metastasis drugs,
these ndings predict that compound 5 would be effective in
controlling metastatic potential of renal tumors.
In summary, compound 5 inhibits thioredoxin reductase
and causes decreased expression of pro-motility enzymes such
as p90-RSK, AKT, and MAPKAPK3 in Caki-1 cells. In contrast,
compound 3 has a more modest inhibitory effect on TrxR in
Caki-1 cells but does not affect expression of the pro-motility
enzymes. Nevertheless, compound 3 was found to reduce the
secretion of IL-6 in Caki-1 cells thereby supporting the
hypothesis that some MAPKAPK2/3 inhibition does occur.31
When Auranon was tested as a negative control compound for
TrRx inhibition studies, it was found to inhibit TrRx in the same
range as compound 5 but failed to down-regulate MAKPAPK-3
in Caki-1 cells (Fig. S46 in ESI‡).
Effects on tumor growth in vivo with compounds 3 and 5
Evaluation of the lethal and maximum tolerated doses. The
lethal dose (LD) and maximum tolerated doses (MTD) of the
most active compound 5 were evaluated in C57/BL6 mice (see
Experimental for details). We had reported on the lethal dose
for previously described 3 evaluated in the same manner.31 The
LD was determined to be 15 mg per kg per day (ref. 31) for 3 and
6 mg per kg per day for 5. No biological samples were collected
from those mice. The MTD was determined to be 10 mg per kg
per day for 3 and 5mg per kg per day for 5, the dose at which the
mice showed no visible signs of distress over the 7 days course
of treatment. The mice did not lose weight during the trial.
24 hours aer the last dose all mice used in the MTD study were
euthanized and blood plasma, liver, spleen and kidneys were
collected and used for histological analysis. Necropsies indicate
that mice treated at 10 mg per kg per day with 3 and 5 mg per kg
per day with 5 showed normal liver and slightly enlarged
spleens.
We therefore chose the dose of 7.5 mg per kg per day for 3
and 3 mg per kg per day for 5 every other day to conduct the
subsequent in vivo trials. The choice of 3 and 5 for a subsequent
in vivo trial was based on their selectivity in vitro against renal
cancer cell lines when compared to non-tumorigenic human
kidney cell lines (HEK-293T and RPTC) and their favourable
preliminary toxicity prole on C57BL/6 mice.
Effects of 3 and 5 in Caki-1 mouse xenogras. 18 female
NOD.CB17-Prkdc scid/J (non-obese diabetic-severe combined
immunodeciency) were selected for the in vivo trial. The mice
were inoculated with Caki-1 cells (see Experimental for details)
and treated when tumors were palpable (about 6 mm diameter).
Each of six Caki-1-transplanted animals received compound 3
(7.5 mg per kg per every other day), or 5 (3 mg per kg per every
other day) or vehicle 0.1% DMSO in (0.9% NaCl) intraperito-
neally (i.p.).
In the group treated with 3we observed no decrease in tumor
size, neither did we observe any hindrance in tumor growth
from the starting volume between day 1 and day 28 of treatment
(aer a total of 14 doses). For this compound we observed a 90%
increase in tumor volume (see Fig. S47 in ESI‡). For the group
Fig. 9 Decreased expression of p90-RSK, AKT, and MAPKAPK-3 in
Caki-1 cells in response to compound 5. Cells were incubated with
either 5, compound 3 or 0.1% DMSO for the indicated times, followed
by cell lysis, and Western blot analysis. Blots were probed with anti-b-
actin antibody as a control for protein loading. Samples from cells
treated with compound 5 are shown in panel A, and samples from cells
treated with compound 3 are shown in panel B.
Table 3 Effects of 3 and 5 on the tumour growth of Caki-1 renal
carcinoma in NOD.CB17-Prkdc scid/J mice
Treatment group Primary tumour (mm3)
Control 397.07  14.96
3 7.5 mg per kg per e.o.da (14) 311.11  9.45
5 3 mg per kg per e.o.da (14) 41.33  13.00
a e.o.d ¼ every other day. Tumour measured on day 28, aer 14th dose.
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treated with 5 we observed an impressive decrease in tumor size
(shrinkage) of 67% from the starting volume between day 1 and
day 28 of treatment (aer a total of 14 doses). In contrast, in the
control vehicle-treated group we observed 106% increase in
tumor volume between day 1 and day 28 of treatment (see Table
3 and Fig. 10). We note that there was no weight loss in mice
treated with treated with either 3 or 5 by this protocol.
The results clearly indicate that compound 5 is extremely
efficient in vivo since it not only inhibits tumor growth but it
decreases the size of the tumors by 67%, while compound 3 has
no notable effect on tumor size.
Pharmacokinetic study
Bio-distribution of compound 3 and compound 5. Bimetallic
compounds like compound 3 and compound 5 can be detected
and quantied by the estimation of both titanium and gold ions
by Inductively Coupled Plasma-Mass Spectromety (ICP-MS).
However, while gold content in tissues is minimal, the levels of
titanium in mouse organs can be quite signicant.67,68 Previous
studies have reported basal levels of titanium to be 0.15 mg
kg1, 1.3 mg kg1 and 1.3 mg kg1 in blood, kidney and liver
respectively.68 In addition, some titanium can also be released
into the samples from the ultrasonic probe during the tissue
disruption. Owing to these confounding factors, it is extremely
difficult to accurately estimate the concentration of titanium
from the compounds of interest. In order to avoid these arti-
facts, only gold levels in blood and tissue were used for quan-
tifying the compounds of interest. The analysis of only the non-
abundant Au metal69 for the calculation of the drug concen-
tration in animal tissues and plasma during our in vivo phar-
macokinetic analysis is further justied by the results obtained
in Caki-1 cells for compound 5 demonstrating the co-localiza-
tion of Ti and Au metals.
Fig. 10 Percent reduction of tumour burden in a cohort of 18 female
NOD.CB17-Prkdc scid/J mice inoculated subcutaneously with 8  106
Caki-1 cells. The treatment started when tumors were palpable (6 mm
diameter). 6 mice were treated with compound 5 (red bars), and 6
were treated with the vehicle 100 mL normal saline (0.9% NaCl) (black
bars). Compound 5was administered in the amount of 3 mg per kg per
every other day.
Fig. 11 Concentration of compounds 3 (A) and 5 (B) in plasma at various intervals after the first dose; data represents mean SD.N¼ 3. Content
of compounds 3 (C) and 5 (D) in tissues at the end of efficacy study; data represents mean  SD; N ¼ 3; P < 0.05.
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Content of compound 3 and compound 5 in blood and
tissues was calculated from their gold content and normalized
to the extraction efficiency of gold in the respective tissues and
blood. The pharmacokinetic prole of compound 3 in mice
(Fig. 11A) is summarized in Table 4.
The compound was absorbed quickly into plasma (t1/2 abs ¼
0.55 h) and the peak plasma concentration was reached aer 2
hours of dosing. The drug was eliminated slowly from the blood
compartment with an elimination half-life (t1/2 e) of about 7.5
hours. The concentration of gold in the blood at 6 hours aer
the last dose of compound 3, was 24.1  2.6 mg mL1, which is
lower (P < 0.01) than the Cmax aer the rst dose and not
signicantly different (P > 0.1) from the blood concentration at 6
hours aer the rst dose. This suggests that compound 3
doesn't accumulate in the blood. On the other hand, the phar-
macokinetic prole of compound 5 (Fig. 11B) was characterized
by a slow absorption with a constant increase in blood levels of
the drug up to 24 hours. At the time of the second dose
(48 hours aer the rst dose), the blood concentration of
compound 5 was 40.4  6.0 mg mL1. At the end of the study,
gold content in liver, kidney and tumor was determined for
compound 3 (Fig. 11C) and compound 5 (Fig. 11D) treatments.
The level of gold in liver and kidney was less than 15 mg g1
tissue weight while the tumor concentration was about 50 mg
g1. The high level in tumor suggests enhanced tumor accu-
mulation of compound 3. On the other hand, compound 5
concentration in the liver and kidney were signicantly higher
than tumor. As mentioned above, pharmacokinetic analysis of
compound 3 in blood was performed based on a non-
compartment model. Blood level of compound 3 aer 48 hours
of dosing was determined to be 45 mg mL1 which was much
greater than the blood level at 24 hours (5.5 mg mL1). Since the
drug was already at the end of the elimination phase at 24
hours, the high level at 48 hour was considered as an outlier and
was not used in the determination of the pharmacokinetic
parameters for compound 3. The blood concentration of
compound 5 increased steadily up to 24 hours and then
decreased at 48 hours. We speculate that the dosing regimen of
the animals (every 48 hours) did not allow for complete elimi-
nation of compound 5 from the animals and thus we could not
estimate the pharmacokinetic prole of this compound.
However, since the multiple dosing demonstrated the superior
efficacy of the compound in tumor bearing mice, we hypothe-
size that the drug effectiveness against tumor is due to the
combination of several factors such as higher accumulation of
the drug in the tumor tissues, longer half-life of the drug in the
body and accumulation of drug in kidney tissue. Future studies
will be aimed at estimating the elimination phase of the
compound by dosing the animals with single dose.
We believe that the impressive tumor reduction shown by 5,
its selectivity for kidney cancer cells in vitro, and low toxicity in
mice in vivo warrant future experiments in vivo to better deter-
mine the ideal dosage and get more accurate pharmacokinetic
data.
Experimental
General and instrumentation for the characterization and
stability studies of the new compounds
NMR spectra were recorded in a Bruker AV400 1H NMR at
400 MHz, 13C{1H} NMR at 100.6 MHz and 31P{1H} NMR at
161.9 MHz. Chemical shis (d) are given in ppm using CDCl3 as
the solvent, unless otherwise stated. 1H and 13C{1H} NMR
resonances were measured relative to solvent peaks considering
tetramethylsilane ¼ 0 ppm, and 31P{1H} NMR was externally
referenced to H3PO4 (85%). Coupling constants J are given in
hertz. IR spectra (4 000 250 cm1) were recorded on a Nicolet
6700 Fourier transform infrared spectrophotometer on solid
state (ATR accessory). Elemental analyses were performed on a
Perkin-Elmer 2400 CHNS/O series II analyzer. Mass spectra
(electrospray ionization, ESI) were performed on a Waters Q-Tof
Ultima. Stability studies were performed in a Cary 100 Bio
UV-visible spectrophotometer. The pH was measured in an
OAKTON pH conductivity meter in 1 : 99 DMSO/H2O solutions.
Synthesis
All compounds involving titanium centers were prepared and
handled with rigorous exclusion of air and moisture under a
nitrogen atmosphere by using standard nitrogen/vacuum
manifold and Schlenk techniques. Solvents were puried by use
of a PureSolv purication unit from Innovative Technology, Inc.
Titanocene dichloride was purchased from Aldrich and 4-mer-
captobenzoic acid from TCI America Inc. and used without
further purication. Complex 4,31 [AuCl(tht)]70 and
[AuCl(MPPF)]71 were prepared as previously reported.
[(h-C5H5)2TiMe(m-mba)Au(PPh3)] (5). Complex 4 (1.174 g,
1.91 mmol) was dissolved in tetrahydrofurane (15 mL) and
added via cannula over a solution of Cp2TiMe2 (0.399 g, 1.91
mmol) in toluene (10 mL) to yield a bright orange solution that
was stirred for 1 hour at room temperature. The solvents were
then removed under reduced pressure and the crude washed
with diethyl ether (3  10 mL). The heterometallic complex was
isolated as a pale orange solid in 85% yield (1.312 g). Anal. calc.
for C36H32AuO2PSTi (804.52) 1 C7H8: C, 57.60; H, 4.50; S, 3.58.
Found: C, 57.66; H, 4.73; S, 3.64. 31P{1H} NMR (CDCl3): d 38.66.
1H NMR (CDCl3): d 7.52 (19H, m, PPh3 + C6H4), d 6.22 (10H, s,
C5H5), d 1.00 (3H, s, CH3–Ti).
13C{1H} NMR (CDCl3): d 171.63 (s,
C]O), d 148.08 (s, 4-C6H4), d 134.21 (d,
2JPC¼ 13.8 Hz, o-PPh3), d
131.88 (s, 2-C6H4), d 131.80 (s, p-PPh3), d 129.29 (d,
1JPC ¼ 49.6
Hz, ipso-PPh3), d 129.28 (d,
3JPC ¼ 11.5 Hz, m-PPh3), d 128.23 (s,







t1/2 e 7.4 h
t1/2 abs 0.6 h
tmax 2.2 h
Cmax 37.7 mg mL
1
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3-C6H4), d 125.30 (s, 1-C6H4), d 114.35 (s, C5H5), d 44.14 (s, CH3).
IR (cm1): 3050 w (Cp), 1631 vs. (nasym CO2), 1435 s (Cp), 1298 vs.
(nsym CO2), 1167 m (Cp), 815 s (Cp). pH 5 (5  105 M in 1 : 99
DMSO : H2O) ¼ 5.13. For comparison, pH of previously
described compound 434 was evaluated (5  105 M in 1 : 99
DMSO : H2O) ¼ 4.90.
[Au(Hmba)(MPPF)] (6). 4-Mercaptobenzoic acid (0.109 g,
0.70 mmol) and KOH (0.040 g, 0.70 mmol) were dissolved in 20
mL of a 4 : 1 EtOH/H2O mixture giving rise to a pale yellow
solution that was stirred at RT for 10 minutes becoming color-
less. The addition of [AuCl(MPPF)] (0.426 g, 0.70 mmol) led to
thick yellow suspension that was stirred for 1 hour at RT. Aer
solvents removal, the crude was washed with water (3  5 mL)
and a 9 : 1 n-hexane/Et2O mixture (3  10 mL). Complex 10 was
then isolated as a ne yellow solid in 89% yield (0.455 g).
Crystals of 6 were obtained from a solution of 6 in CH2Cl2
layered with n-hexane at RT as orange prisms. Anal. calc. for
C29H24AuFeO2PS (720.35): C, 48.35; H, 3.36; S, 4.45. Found: C,
48.46; H, 3.37; S, 4.60. 31P{1H} NMR (CDCl3): d 34.04.
1H NMR
(CDCl3): d 10.58 (1H, s, COOH), d 7.87 (2H, d,
3JHH ¼ 8.3 Hz, 2-
C6H4), d 7.77 (2H, d,
3JHH¼ 8.3 Hz, 3-C6H4), d 7.63 (4H, m, PPh2),
d 7.50 (6H, m PPh2), d 4.60 (2H, s, C5H4), d 4.41 (2H, s, C5H4), d
4.20 (5H, s, C5H5).
13C{1H} NMR (CDCl3): d 170.89 (s, C]O), d
152.47 (s, 4-C6H4), d 133.58 (d,
2JPC ¼ 13.8 Hz, o-PPh2), d 132.14
(s, 2-C6H4), d 131.47 (d,
4JPC ¼ 2.4 Hz, p-PPh2), d 131.46 (d, 1JPC¼
58.7 Hz, ipso-PPh2), d 129.78 (s, 3-C6H4), d 128.94 (d,
3JPC ¼ 11.9
Hz, m-PPh2), d 123.77 (s, 1-C6H4), d 73.46 (d,
2JPC ¼ 13.8 Hz,
C5H4), 72.52 (d,
3JPC ¼ 8.7 Hz, C5H4), 70.06 (s, C5H5). IR (cm1):
3069 w (OH), 1674 vs. (nasym CO2), 1416 vs. (nsym CO2). pH 6 (5 
105 M in 1 : 99 DMSO : H2O) ¼ 4.99.
[(h-C5H5)2TiMe(m-mba)Au(MPPF)] (7). Complex 6 (0.402 g,
0.56 mmol) was dissolved in acetonitrile (15 mL) and added via
cannula over a solution of Cp2TiMe2 (0.117 g, 0.56 mmol) in
toluene (5 mL) to yield an orange solution that was stirred for 1
hour at RT. The solvents were then removed under reduced
pressure and the crude washed with diethyl ether (3  10 mL).
The heterometallic complex was isolated as a orange solid in
81% yield (0.415 g). Anal. calc. for C40H36AuFeO2PSTi (912.44):
C, 52.65; H, 3.98; S, 3.51. Found: C, 52.89; H, 4.04; S, 3.47. 31P
{1H} NMR (CDCl3): d 33.76.
1H NMR (CDCl3): d 7.64 (6H, m, PPh3
+ C6H4), d 7.49 (8H, m, PPh3 + C6H4), d 6.22 (10H, s, 2C5H5–Ti), d
4.59 (2H, s, C5H4–Fe), d 4.39 (2H, s, C5H4–Fe), d 4.18 (5H, s,
C5H5–Fe), d 1.00 (3H, s, CH3).
13C{1H} NMR (CDCl3): d 171.70 (s,
C]O), d 148.23 (s, 4-C6H4), d 133.60 (d,
2JPC¼ 13.7 Hz, o-PPh2), d
132.02 (s, 2-C6H4), d 131.41 (d,
4JPC¼ 1.7 Hz, p-PPh2), d 129.57 (s,
3-C6H4), d 128.89 (d,
3JPC ¼ 11.4 Hz, m-PPh2), d 128.64 (d, 1JPC ¼
81.5 Hz, ipso-PPh2), d 125.31 (s, 1-C6H4), d 114.34 (s, C5H5), d
73.47 (d, 2JPC ¼ 13.8 Hz, C5H4), 72.48 (d, 3JPC ¼ 8.6 Hz, C5H4),
70.07 (s, C5H5), d 44.14 (s, CH3). IR (cm
1): 3086 w (Cp), 1633 vs.
(nasym CO2), 1479 s (Cp), 1299 vs. (nsym CO2), 1168 m (Cp), 817 s
(Cp). pH 7 (5  105 M in 1 : 99 DMSO : H2O) ¼ 5.21.
Crystal structure determination
Single crystals of 6 (orange prisms with approximate dimen-
sions 0.25 0.23 0.23 mm) were mounted on a glass ber in a
random orientation. Data collection was performed at room
temperature on a Kappa CCD diffractometer using graphite
monochromated Mo-Ka radiation (l ¼ 0.71073 Å). Space group
assignments were based on systematic absences, E statistics
and successful renement of the structures. The structures were
solved by direct methods with the aid of successive difference
Fourier maps and were rened using the SHELXTL 6.1 soware
package. All non-hydrogen atoms were rened anisotropically.
Hydrogen atoms were assigned to ideal positions and rened
using a riding model (ESI‡).
DFT calculations
The calculations have been performed using the hybrid density
functional method B3LYP,72,73 as implemented in Gaussian09.74
Geometries were optimized with the 6-311G(d) basis set for the
P and S elements, the 6-31G(d,p) basis set for the C, N, P, S, and
H elements and the SDD pseudopotential for the titanium, iron
and gold metal centers.75,76 Frequency calculations have been
done at the same level of theory as the geometry optimizations
to conrm the nature of the stationary points.
Cell culture
Human renal cell carcinoma lines A498, Caki-1 and UO31, as
well as the human prostate carcinoma cell lines DU145 and PC3
were newly obtained for these studies from the American Type
Culture Collection (ATCC) (Manassas, Virginia, USA) and
cultured in Roswell Park Memorial Institute (RPMI-1640)
(Mediatech Inc., Manassas, VA) media containing 10% fetal
bovine serum (FBS, Life Technologies, Grand Island, NY), 1%
Minimum Essential Media (MEM) nonessential amino acids
(NEAA, Mediatech) and 1% penicillin–streptomycin (PenStrep,
Mediatech). HEK-293T cells were newly purchased from ATCC
(Manassas, Virginia, USA) and maintained in Dulbecco's
modied Eagle's medium (DMEM) (Mediatech) supplemented
with 10% FBS, 1% NEAA and 1% PenStrep. Normal human
renal epithelial cells (RPTC) were purchased from Lifeline Cell
Technology (Lifeline Cell Technology, Frederick, MD, USA) and
maintained in Lifeline's Renal Life Medium from Lifeline Cell
Technology supplemented with 2.4 mM L-glutamine, 5 mg mL1
rh insulin, 1.0 nM epinephrine, 10 nM triiodothyronine, 0.1 mg
mL1 hydrocortisone hemisuccinate, 10 ng mL1 rhEGF, 0.50%
FBS, 5 mg mL1 transferrin PS. All cells were cultured at 37 C
and 5% CO2 in a humidied incubator.
Cell viability assay
Cells were seeded at a concentration of 5000 cells/90 mL per well
of either RPMI or DMEM without phenol red and without
antibiotics, supplemented with 10% FBS and 2 mM L-glutamine
into tissue culture grade 96-well at bottom microplates
(BioLite Microwell Plate, Fisher Scientic, Waltham, Massa-
chusetts, USA) and grown for 24 h at 37 C in a humidied
incubator. Aerwards, the intermediate dilutions of the
compounds were added to the wells (10 mL) to obtain a nal
concentration ranging from 0.1 to 200 mM, and the cells were
incubated for 24 h or 72 h. Following 24 h or 72 h drug exposure,
50 mL per well of 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) (Roche Diagnostics,
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Indianapolis, Indiana, USA) labelling mixture was added to the
cells at a nal concentration of 0.3 mgmL1 and incubated for 4
h at 37 C in a humidied incubator. The optical absorbance of
each well in a 96-well plate was quantied using BioTek ELx808
absorbance microplate reader (BioTek Winooski, VT) set at
450 nm wavelength. The percentage of surviving cells was
calculated from the ratio of absorbance of treated to untreated
cells. The IC50 value was calculated as the concentration
reducing the proliferation of the cells by 50% and is presented
as a mean (S.E.) of at least two independent experiments each
with triplicate measurements.
Stability of compound 5 in vitro and co-localization of Ti/Au
metals in Caki-1 cells
Caki-1 cells were incubated with 1 mMand 5 mM compound 5 for
24 hours. Post-incubation, the cells were washed twice with cold
PBS and lysed with cell lysis buffer comprising of 1% (v/v)
Triton-X-100, 25 mM HEPES, 100 mM NaCl, 1 mM EDTA, 10%
(v/v) glycerol and protease and phosphatase inhibitors. Lysates
from untreated cells incubated with media supplemented with
DMSO for same duration, were used as controls. Gold and
titanium content in the cell lysates was determined using ICP-
MS. One hundred mL of lysates were transferred into a glass vials
and 1 mL of concentrated acid mix (comprising of 75% of 16 N
nitric acid and 25% of 12 N hydrochloric acid) was added. The
mixture was heated at 90 C for 5 hours. Aer cooling, the
samples were diluted with water, 40 ppb of Indium internal
standard was added and analyzed in a Thermo Scientic
XSERIES 2 ICP-MS with ESI PC3 Peltier cooled spray chamber
with SC-FAST injection loop and SC-4 autosampler. All the
elements were analyzed using He/H2 collision-reaction mode.
One micromole of compound 5 was processed similarly to
determine the extraction efficiency of gold and titanium. The
protein content of the cell lysates were determined using
bicinchoninic acid based protein assay kit (Thermo Scientic).
The nal levels of either Ti or Au were normalized to the cellular
protein levels.
Annexin V/PI assay
Conuent Caki-1 cells were treated with either 10 mM of 5, 0.1%
DMSO or 5 mMof staurosporine for 6 h (Fig. 5). Aer incubation,
cells were trypsinized with 0.25% trypsin without EDTA (Life
Technologies, NY, USA) and stained for extracellular phospha-
tidylserine expression using FITC conjugated annexin V to label
early apoptotic cells and co-stained with propidium iodide (PI)
to identify necrotic cells according to the manufacturer
instructions for the dyes (BD Biosciences, San Jose, CA). Stained
cells were analyzed by ow cytometry using Accuri C6 soware
(BD Biosciences, San Jose, CA, USA).
Cell migration
For wound healing assays, Caki-1 cells were seeded in 6 cm
dishes at a density of 0.8  106 in complete media, then grown
to conuence for 24 hours at 37 C (5% CO2), then cross-shape
wounds/scratches were performed in the monolayer using a
sterile 10 mL pipette tip. Following the treatment of conuent
cells with 5 mM compound 3 or 5 or 0.1% DMSO as control,
images of wounds were captured by light microscopy using the
Labomed TCM 400 Inverted Research Microscope (Abo America
Inc., Fremont, CA) and a digital Moticam 10 camera(Fisher
Scientic Pittsberg, PA) immediately aer scratching (T0), aer
1 hour (T1) and aer 12 h (T12). To quantify cell migration, the
area of the initial wound (T0) is compared with the area of the
healing wound at three time points aer the scratch is intro-
duced. Percent migration ¼ [area of original wound  area of
wound during healing]/area of original wound]  100.77
Mobility shi assay
10 mL aliquots of pBR322 plasmid DNA (20 mg mL1) in buffer
(5 mM Tris/HCl, 50 mM NaClO4, pH ¼ 7.39) were incubated
with different concentrations of the compounds (4–7, and tita-
nocene dichloride) (in the range 0.25 and 4.0 metal complex-
: DNA bp) at 37 C for 20 h in the dark. Samples of free DNA and
cisplatin–DNA were prepared as controls. Aer the incubation
period, the samples were loaded onto the 1% agarose gel. The
samples were separated by electrophoresis for 1.5 h at 80 V in
Tris–acetate/EDTA buffer (TAE). Aerwards, the gel was stained
for 30 min with a solution of GelRed nucleic acid stain.
Thioredoxin reductase inhibition studies in Caki-1 cells
For thioredoxin reductase activity assays, whole cell lysates was
obtained from Caki-1 cells treated in vitro with either 0.1 mM,
0.5 mM, 1 mM, or 5 mM of 3, 5 or Auranon or 1% DMSO. Aer 5,
12 or 24 hours of treatment incubation cells were washed three
times in PBS, and lysed by douncing using scrapers and sheer
force though syringe with a 34 gauge needle in assay buffer
(Abcam Thioredoxin Reductase Assay kit, ab83463) added to
1 mM protease inhibitor cocktail (Abcam, ab65621). The lysates
were centrifuged at 10 000  g for 15 minutes at 4 C to isolate
insoluble material. The total protein concentrations of soluble
lysates were measured using the BCA Protein Assay (Life Tech-
nologies). The soluble lysates were incubated for 20 minutes in
assay buffer before adding DTNB (5,50-dithiobis(2-nitrobenzoic)
acid), and measuring activity at 1 minute intervals for
30 minutes using the BioTek uorescence microplate reader
(BioTek U.S., Winooski, VT) set at l ¼ 412 nm. Lysates were
tested in duplicate. TrxR activity was calculated based on the
linear amount of TNB produced per minute per mg of total
protein and corrected for background activity from enzymes
other than TrxR in the lysates.
Kinase inhibition studies
In vitro proling of a 35 selected member protein kinase panel
(see ESI‡) was performed at Reaction Biology Corporation using
the “HotSpot” assay platform. Briey, specic kinase/substrate
pairs along with required cofactors78 were prepared in reaction
buffer; 20 mMHepes pH 7.5, 10 mMMgCl2, 1 mM EGTA, 0.02%
Brij35, 0.02 mg mL1 BSA, 0.1 mM Na3VO4, 2 mM DTT, 1%
DMSO. Compounds were delivered into the reaction, followed
20 min later by addition of a mixture of ATP (Sigma) and
33P-ATP (Perkin Elmer) to a nal concentration 10 mM. Reac-
tions were carried out at 25 C for 120 min, followed by spotting
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5269–5283 | 5279































































































of the reactions onto P81 ion exchange lter paper (Whatman).
Unbound phosphate was removed by extensive washing of
lters in 0.75% phosphoric acid. Aer subtraction of back-
ground derived from control reactions containing inactive
enzyme, kinase activity data were expressed as the percent
remaining kinase activity in test samples compared to vehicle
(dimethyl sulfoxide) reactions. IC50 values and curve ts were
obtained using Prism (GraphPad Soware).
Cell lysis and immunoblotting
Caki-1 cells were seeded into 10 cm dishes at a density of 2.2 
106 and incubated for 24 hours. Following the treatment of
conuent cells with 5 mM of compound 3 or 5 and 0.1% DMSO
as control for either 1 hour, 3 hours, 6 hours or 12 hours, the
cultures were washed with cold PBS, and the cells were har-
vested by scraping with a rubber cell scraper. Aer micro-
centrifuging for 5 minutes at 4 C, pellets were treated with ice-
cold lysis buffer with cell extraction buffer (BioSource, Cama-
rillo, CA) containing 0.1% protease inhibitors and 1% phos-
phatase inhibitors cocktail (Fisher Scientic, Pittsburg, PA) for
10 minutes, then sonicated for 10 seconds three times, and
placed on ice. The lysed cells were centrifuged at 10 000  g at
4 C for 10 minutes to remove the pellets representing the
insoluble cell fraction.
The protein concentration was determined with BCA protein
dye reagent (Pierce, Fisher Scientic Pittsberg, PA). Samples
were denatured with 5 SDS sample buffer 0.25% bromophenol
blue, 0.5 M dithiothreitol (DTT), 50% glycerol 50% (v/v), 10%
sodium dodecyl sulfate (SDS) followed by heating at 95 C for
5 minutes. Proteins were separated by SDS-PAGE, transferred to
a PVDF membrane (Millipore Corp.), and probed with MAP-
KAPK-3 antibody (Cell Signaling Technology, Danvers, MA,
USA), as well as b-actin antibody (Cell Signaling Technology,
Danvers, MA, USA). Immunoreactive bands of primary anti-
bodies were detected using HRP goat anti-rabbit and secondary
antibodies were detected with peroxidase-conjugated secondary
antibody and detected by chemiluminescence (Pierce Biotech-
nology, Rockford, IL).
Determination of lethal and maximum tolerated doses (LD
and MTD) in mice
The preliminary toxicity testing of compound 5 was performed
in C57BL/6 female mice 6 to 8 weeks of age, maintained in
accordance with institutional guidelines at the University of
Hawaii Cancer Center (UHCC) governing the care of laboratory
animals (IACUC number: A3423-01). To determine the lethal
dose, mice were treated for 5 consecutive days at dosages
ranging from 1.5 mg per kg per day to 6 mg per kg per day. We
used one mouse per dose. Mice were weighed every 48 hours,
and sacriced 24 hours aer the last dose. The compounds were
administered in a solution of 0.5% DMSO and 99.5% normal
saline (0.9% NaCl) (G-Biosciences, St. Louis, MO, U.S.A) once
daily by subcutaneous injection. In order to determine the
maximum tolerated dose (MTD) the animals were monitored by
trained individuals for pain and distress as appropriate for the
animal, under conditions and by procedures established by the
UHCC vivarium veterinarian staff and research personnel (BTE).
The maximum tolerated dose (MTD) was determined by
observing the progression of the mice treated at doses below the
lethal dose. Body weights, changes in behaviour and sign of
distress were recorded. The dose at which neither debilitating
effects nor sign of distress were observed was set as the MTD.
More specically the signs for distress monitored were: (1)
decreased food and water consumption; (2) weight loss (more
than 20% loss in body weight or dropping at or below 18 g) was
consistent with signicant distress and mice exhibiting such
weight loss were euthanized; (3) abnormal posture/positioning
(e.g., head-pressing, hunched back); (4) unkempt appearance
(erected, matted, or dull haircoat); (5) self-mutilation, gnawing
at limbs; (6) excessive self-imposed isolation/hiding. The MTD
dose was conrmed by treating a cohort of 3 mice per
compound and one control group, every other day for 14 days
with the MTD dose. One group of mice was treated with the
solvent (negative control). During the trial the mice did not
exhibit any signs of distress.
Study of the effects of 2 in Caki-1 xenogras in mice
12 female NOD.CB17-Prkdc scid/J (non-obese diabetic–severe
combined immunodeciency) from Jackson Laboratory (Bar
Harbor, ME and Sacramento, CA, USA) were used for the
xenogra experiment (ages 8 to 12 weeks and weighing 19–22 g)
were used. Each mouse received 8  106 tumor cells subcuta-
neously without anesthesia. Exponentially growing Caki-1
human kidney cancer cells were suspended in 1 : 1 ratio 50 mL
phosphate-buffered saline (PBS; pH 7.4) plus 50 mL of matrigel
(BD Biosciences, San Jose, CA, USA) were injected subcutane-
ously on both le and right ank of each mice. The diameter of
the tumors was measured once weekly using an electronic
digital caliper and the tumor volume (TV) was calculated
according to the empirical equation TV ¼ (a)(b2)  p/6 where
a ¼ longest dimension; b ¼ largest dimension orthogonal to
a. The median volumes of each group were normalized to the
initial tumor volume resulting in the relative tumor volume.
Each group of six Caki-1-transplanted animals received
compound 3 (7.5 mg per kg per every other day), compound 5
(3 mg per kg per every other day) or vehicle (0.1% DMSO in 0.9%
NaCl) intraperitoneally (i.p.). Treatment started when tumors
were palpable (about 6 mm diameter). Mice were randomized to
treatment groups based on their starting tumour burden at
12 weeks of age to ensure equivalent distribution between the
3 groups. At trial end-point the mice were sacriced and tumors
measured again aer excision and then processed for further
analysis. Histological as well as biochemical evaluations of
blood, liver, spleen, and kidney, were conducted. Tumor
volumes were graphed for 3 and 5 treated mice compared to
vehicle-treated mice, based on weekly external digital caliper
measurements.
Bio-distribution: determination of gold and titanium content
in the organs and plasma
Female NOD.CB17-Prkdc scid/J bearing subcutaneous Caki-1
tumors and treated with subcutaneous injection of either
5280 | Chem. Sci., 2015, 6, 5269–5283 This journal is © The Royal Society of Chemistry 2015































































































compound # 3 (7.5 mg per kg per 48 hours) or compound 5
(3 mg per kg per 48 hours) were used for pharmacokinetic
distribution of the drug in blood and other tissues. Blood was
collected by retro-orbital bleeding into heparinized blood
collection vials on ice at time intervals of 30 minutes, 2 hours,
6 hours, 24 hours, and 48 hours aer the rst dose. The blood
samples were centrifuged at 2800 rpm at 4 C for 15 min and the
supernatant plasma was transferred into 1.5 mL micro-centri-
fuge tubes and stored at 80 C until further analysis.
Gold and titanium content was determined using ICP-MS.
In brief, y microliters of plasma was transferred into a glass
vial and 1 mL of concentrated acid mix (comprising of 75% of
16 N nitric acid and 25% of 12 N hydrochloric acid) was added.
The mixture was heated at 90 C for 5 hours. Aer cooling, the
samples were diluted with water, 40 ppb of Indium internal
standard was added and analyzed in a Thermo Scientic
XSERIES 2 ICP-MS with ESI PC3 Peltier cooled spray chamber
with SC-FAST injection loop and SC-4 autosampler. All the
elements were analyzed using He/H2 collision-reaction mode.
Plasma from control mice was spiked with the test
compounds to determine the extraction efficiency of gold and
titanium.
At the end of the study, liver, kidney and tumor of the
animals were harvested, weighed and transferred into glass
vials. One mL of water was added to each samples and sub-
jected to ultrasonic tissue disruption at 15 W power for
1 minute. The tissue homogenates were frozen at 80 C for
2 hours and lyophilized. The lyophilized product was heated at
90 C with the concentrated acid mix (described above) for
5 hours, cooled, diluted with water and analyzed for titanium
and gold by ICP-MS. Pharmacokinetic estimates were obtained
from the plasma concentration–time proles by non-
compartmental analysis.
Conclusions
In conclusion we have described the preparation and prom-
ising antitumor properties of a new, unusually stable titano-
cene heterometallic compound containing a methyl group and
a carboxylate ligand (mba ¼ S–C6H4–COO) bound to a
gold(I)-triphenylphosphane fragment through a thiolate group
[(h-C5H5)2TiMe(m-mba)Au(PPh3)] (5). This compound is able to
block renal cancer growth both in vitro and in vivo by path-
way(s) that involve the inhibition of thioredoxin reductase and
decreased expression of proteins kinases known to drive cell
migration. Preliminary evidence indicates that compound 5
may have appreciable anti-invasive properties. In addition its
robustness has been demonstrated in cellular uptake experi-
ments on Caki-1 cells by co-localization of Ti and Au metals in
a 1 : 1 ratio. The impressive tumor reduction (67%) observed
in the in vivo trial with mice warrants further in vivo studies to
better determine the minimum most effective dosage and to
get more accurate pharmacokinetic data. Studies on the
mechanism(s) of this compound and effects on other cancers
are under way. Overall, our results strongly support the efficacy
of multifunctional heterometallic compounds, thus high-
lighting their great chemotherapeutic potential.
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